Dyne Therapeutics (DYN) News Today $11.82 -0.42 (-3.43%) Closing price 04:00 PM EasternExtended Trading$11.96 +0.15 (+1.23%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Evercore ISI Initiates Coverage on Dyne Therapeutics (NASDAQ:DYN)Evercore ISI began coverage on shares of Dyne Therapeutics in a report on Thursday. They set an "outperform" rating and a $46.00 target price on the stock.May 30 at 8:40 AM | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of "Buy" by BrokeragesShares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have been given an average recommendation of "Buy" by the fourteen ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, eleven have given a buy recommendMay 30 at 3:06 AM | marketbeat.comVoloridge Investment Management LLC Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)Voloridge Investment Management LLC bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 119,015 shares of the company's stock, valued aMay 29 at 4:29 AM | marketbeat.comDeutsche Bank AG Has $1.67 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Deutsche Bank AG raised its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 51.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 70,961 shares of the company's stock after bMay 26, 2025 | marketbeat.comWoodline Partners LP Sells 403,483 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Woodline Partners LP trimmed its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 41.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 573,957 shares of the company's stock after selling 403,483 shares duMay 24, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Purchased by D. E. Shaw & Co. Inc.D. E. Shaw & Co. Inc. increased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 83.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 133,772 shares of the company'sMay 21, 2025 | marketbeat.com66,998 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by BNP Paribas Financial MarketsBNP Paribas Financial Markets acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 66,998 shares of the company's stock, valued at approximately $1,578,000May 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Purchases 822,201 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Point72 Asset Management L.P. grew its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 802.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 924,681 shares of the company's stock after acquiring an additional 822,201 shares duMay 20, 2025 | marketbeat.comMan Group plc Has $17.59 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Man Group plc raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 3.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 746,463 shares of the company's stock after purchasiMay 19, 2025 | marketbeat.comSphera Funds Management LTD. Grows Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)Sphera Funds Management LTD. grew its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 318.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 236,262 shares of the company'May 18, 2025 | marketbeat.comRTW Investments LP Sells 1,600,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)RTW Investments LP reduced its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 23.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,218,641 shares of the company's stock after selling 1,600,000 shares during theMay 18, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 66,569 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Dimensional Fund Advisors LP cut its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 40.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 99,578 shares of the company's stock aftMay 17, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Position Boosted by Comerica BankComerica Bank grew its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 20,133.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,409 shares of the company's stock after purchasing an additional 35,May 16, 2025 | marketbeat.comNorthern Trust Corp Increases Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Northern Trust Corp boosted its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 7.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 777,013 shares of the company's stock after buying an additiMay 16, 2025 | marketbeat.comOrbimed Advisors LLC Purchases 518,680 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Orbimed Advisors LLC raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 73.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,227,080 shares of the company's stock after buying an additioMay 15, 2025 | marketbeat.comOctagon Capital Advisors LP Has $15.74 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Octagon Capital Advisors LP lifted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 154.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 668,000 shares of the company's stocMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Invests $3.53 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN)Integral Health Asset Management LLC purchased a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 150,000 shares of the compaMay 14, 2025 | marketbeat.comJanus Henderson Group PLC Has $173.81 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Janus Henderson Group PLC lifted its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 8.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,379,309 shares of the company's stock after purchasinMay 14, 2025 | marketbeat.comJefferies Financial Group Inc. Buys Shares of 1,800,000 Dyne Therapeutics, Inc. (NASDAQ:DYN)Jefferies Financial Group Inc. purchased a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,800,000 shares of the compMay 13, 2025 | marketbeat.comCubist Systematic Strategies LLC Buys Shares of 119,065 Dyne Therapeutics, Inc. (NASDAQ:DYN)Cubist Systematic Strategies LLC purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 119,065 shares of the company's stock, valued atMay 13, 2025 | marketbeat.comBalyasny Asset Management L.P. Cuts Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Balyasny Asset Management L.P. trimmed its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 30.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 169,306 shares of the company's stocMay 13, 2025 | marketbeat.comFrontier Capital Management Co. LLC Buys Shares of 298,052 Dyne Therapeutics, Inc. (NASDAQ:DYN)Frontier Capital Management Co. LLC purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 298,052 shares of the company's stock, valued at approximately $7,022,000. FrontieMay 12, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Price Target Cut to $38.00 by Analysts at HC WainwrightHC Wainwright reduced their price target on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research report on Friday.May 11, 2025 | marketbeat.comChardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)Chardan Capital reiterated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Friday.May 11, 2025 | marketbeat.comFarallon Capital Management LLC Trims Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Farallon Capital Management LLC lowered its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 46.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 229,121 shares of the company's stock after selling 198,879 shares during the periodMay 11, 2025 | marketbeat.comFcpm Iii Services B.V. Sells 491,223 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Fcpm Iii Services B.V. cut its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 8.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,462,846 shares of the company's stock after selling 491,223 shares during tMay 11, 2025 | marketbeat.comBrevan Howard Capital Management LP Invests $678,000 in Dyne Therapeutics, Inc. (NASDAQ:DYN)Brevan Howard Capital Management LP bought a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 28,781 sharMay 11, 2025 | marketbeat.comDyne Therapeutics, Inc. Q1 Loss Increases, Misses EstimatesMay 10, 2025 | nasdaq.comDeep Track Capital LP Has $47.12 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Deep Track Capital LP lessened its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 39.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,000,000 shares of the company's stock after sellMay 9, 2025 | marketbeat.comCrestline Management LP Boosts Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)Crestline Management LP lifted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 57.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 184,818 shares of the company's stock after purcMay 9, 2025 | marketbeat.comDyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 9, 2025 | finanznachrichten.deDyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 8, 2025 | globenewswire.comBraidwell LP Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)Braidwell LP bought a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 681,182 shares of the company's stock, valued at approximatelyMay 8, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Bought by ArrowMark Colorado Holdings LLCArrowMark Colorado Holdings LLC increased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 3.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 932,231 shares of the company's stock after purchasing an additional 32,041 shares during the perMay 5, 2025 | marketbeat.comMarshall Wace LLP Makes New $577,000 Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)Marshall Wace LLP purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 24,501 shares of the company's stock, valued at approximately $577,000. Other institutional investors andMay 5, 2025 | marketbeat.comRaymond James Financial Inc. Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Raymond James Financial Inc. purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 99,328 shares of the company's stock, valued at approximately $2,340,000. Raymond James Financial Inc.May 2, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Up 3.9% - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Trading 3.9% Higher - What's Next?May 1, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Decreases Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Price T Rowe Associates Inc. MD decreased its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 8.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,402,452May 1, 2025 | marketbeat.comFirst Light Asset Management LLC Has $9.91 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)First Light Asset Management LLC decreased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 66.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 420,431 shares of the company's stock after selling 836,854 shares durinApril 30, 2025 | marketbeat.comLegal & General Group Plc Has $1.61 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Legal & General Group Plc lessened its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 38.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 68,465 shares of the company's stock after selling 43,192April 28, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. lessened its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 18.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,950,000 shares of the company's stoApril 27, 2025 | marketbeat.comDyne Therapeutics (DYN) to Release Quarterly Earnings on ThursdayDyne Therapeutics (NASDAQ:DYN) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-dyne-therapeutics-inc-stock-1/)April 26, 2025 | marketbeat.comIs Dyne Therapeutics Inc. (NASDAQ:DYN) the Most Promising Small-Cap Stock According to Analysts?April 26, 2025 | insidermonkey.comEC grants orphan drug designation to Dyne Therapeutics’ DMD therapyApril 25, 2025 | finance.yahoo.comDyne Therapeutics stock rises on orphan drug statusApril 24, 2025 | au.investing.comDyne Therapeutics receives EMA orphan drug designation for DYNE-251April 24, 2025 | markets.businessinsider.comDyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular DystrophyApril 24, 2025 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Shares Up 4% - What's Next?Dyne Therapeutics (NASDAQ:DYN) Stock Price Up 4% - Should You Buy?April 23, 2025 | marketbeat.comJump Financial LLC Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Jump Financial LLC acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 50,911 shares of the company's stock, valued at approximately $1,199April 23, 2025 | marketbeat.comWhy Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable BoostApril 21, 2025 | msn.com Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address DYN Media Mentions By Week DYN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼1.040.87▲Average Medical News Sentiment DYN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼87▲DYN Articles Average Week Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Legend Biotech News Today Nuvalent News Today Axsome Therapeutics News Today Lantheus News Today ADMA Biologics News Today Vaxcyte News Today Rhythm Pharmaceuticals News Today Merus News Today Sarepta Therapeutics News Today Akero Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHISTORIC Gold Move Sends Flashing Red Signal To 401K SaversHistorically, when panic hits Wall Street, investors rush to raise cash to cover their leveraged positions be ...Colonial Metals | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
